Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI).
Feliu J, Potter V, Grimaldi F, Clay J, Floro L, Saha C, Barber L, Orti G, Alnagar AA, Garcia-Muñoz R, Kenyon M, Krishnamurthy P, de Lavallade H, Raj K, McLornan D, Pagliuca A, Mufti GJ. Feliu J, et al. Among authors: saha c. Bone Marrow Transplant. 2020 Mar;55(3):562-569. doi: 10.1038/s41409-019-0695-x. Epub 2019 Sep 26. Bone Marrow Transplant. 2020. PMID: 31558789
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients.
Harrington P, Doores KJ, Saha C, Saunders J, Child F, Dillon R, Saglam S, Raj K, McLornan D, Avenoso D, Kordasti S, O'Reilly A, Espehana A, Lechmere T, Khan H, Malim MH, Harrison C, Mehra V, de Lavallade H. Harrington P, et al. Among authors: saha c. Cancer Cell. 2021 Nov 8;39(11):1448-1449. doi: 10.1016/j.ccell.2021.10.002. Epub 2021 Oct 12. Cancer Cell. 2021. PMID: 34717827 Free PMC article. No abstract available.
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients.
Harrington P, Doores KJ, Saha C, Saunders J, Child F, Dillon R, Saglam S, Raj K, McLornan D, Avenoso D, Kordasti S, O'Reilly A, Espehana A, Lechmere T, Khan H, Malim MH, Harrison C, Mehra V, de Lavallade H. Harrington P, et al. Among authors: saha c. Cancer Cell. 2021 Dec 13;39(12):1654. doi: 10.1016/j.ccell.2021.11.011. Cancer Cell. 2021. PMID: 34906318 Free PMC article. No abstract available.
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.
Harrington P, Doores KJ, Saunders J, de Lord M, Saha C, Lechmere T, Khan H, Lam HPJ, Reilly AO, Woodley C, Asirvatham S, Dillon R, Curto-Garcia N, Sullivan JO, Kordasti S, Raj K, Malim MH, Radia D, McLornan D, Harrison C, de Lavallade H. Harrington P, et al. Among authors: saha c. Blood Cancer J. 2022 Apr 22;12(4):73. doi: 10.1038/s41408-022-00651-3. Blood Cancer J. 2022. PMID: 35459222 Free PMC article. No abstract available.
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders.
Harrington P, Kurshan A, Delord M, Lechmere T, Sheikh A, Saunders J, Saha C, Dillon R, Woodley C, Asirvatham S, Curto-Garcia N, Sullivan JO, Kordasti S, Radia D, McLornan D, Malim MH, Harrison C, Doores KJ, de Lavallade H. Harrington P, et al. Among authors: saha c. Blood Adv. 2023 May 23;7(10):1954-1957. doi: 10.1182/bloodadvances.2022008375. Blood Adv. 2023. PMID: 36083126 Free PMC article. No abstract available.
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).
Okikiolu J, Woodley C, Cadman-Davies L, O'Sullivan J, Radia D, Garcia NC, Harrington P, Kordasti S, Asirvatham S, Sriskandarajah P, Saunders J, Saha C, Sanchez I, deLavallade H, McLornan DP, Harrison CN. Okikiolu J, et al. Among authors: saha c. Leuk Res Rep. 2022 Dec 16;19:100360. doi: 10.1016/j.lrr.2022.100360. eCollection 2023. Leuk Res Rep. 2022. PMID: 36590864 Free PMC article.
Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial.
Russell J, Collins A, Fowler A, Karanth M, Saha C, Docherty S, Padayatty J, Maw K, Lentell I, Cooke L, Hodson A, Shah N, Sadullah S, Grigoropoulos N, Qian W, Kirkwood AA, Uttenthal BJ, Johnson P, Follows GA. Russell J, et al. Among authors: saha c. Ann Hematol. 2021 Apr;100(4):1049-1058. doi: 10.1007/s00277-021-04460-9. Epub 2021 Feb 27. Ann Hematol. 2021. PMID: 33641019 Free PMC article.
255 results